PATENT CLAIM ANALYSIS

Application Number: 15872592
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "135100"]

Abstract:
Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.

Claim (Index 10):
The nucleic acid according to  claim 1 , which comprises the nucleic acid sequences of SEQ ID NO:33 and SEQ ID NO:41.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 86.0
- Lexical Diversity: 1.53333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14931149', '13419203', '14146566', '14267028', '13974275']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7325245412425602
- 35 USC 102 Novelty (BERT): 0.5628866907289579
- Combined Prediction Score: 0.7155607561912
- Mean Citation Score: 364.277688
- Max Citation Score: 476.40665
- Similarity Product: 289.22943512921336

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test